An announcement from Immutep Ltd ( (AU:IMM) ) is now available.
Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung ...
Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for ...
Shares in Immutep have leapt after the biotech reported phase 2b results showing that LAG-3 inhibitor eftilagimod alfa (efti) significantly boosted the efficacy of MSD’s Keytruda in patients ...
SYDNEY, AUSTRALIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology ...
Hosted on MSN22d
Immutep Ltd Reveals Key LAG-3 Binding DiscoveryImmutep Ltd (AU:IMM) has released an update. Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart ...
Immutep (IMMP) announces the initiation of the pivotal TACTI-004 Phase III clinical trial for the treatment of first-line metastatic non-small cell lung cancer, 1L NSCLC. “The receipt of ...
Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback